CN102526171A - Eye health care product capable of preventing and delaying senile macular degeneration and manufacture method - Google Patents
Eye health care product capable of preventing and delaying senile macular degeneration and manufacture method Download PDFInfo
- Publication number
- CN102526171A CN102526171A CN2012100277000A CN201210027700A CN102526171A CN 102526171 A CN102526171 A CN 102526171A CN 2012100277000 A CN2012100277000 A CN 2012100277000A CN 201210027700 A CN201210027700 A CN 201210027700A CN 102526171 A CN102526171 A CN 102526171A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- delay
- care article
- chlorella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an eye health care product capable of preventing and delaying senile macular degeneration and a manufacture method. The eye health care product comprises ingredients by weight by part: 20 parts to 30 parts of chlorella extractives, 10 parts to 25 parts of kiwi fruit extractives, 15 parts to 20 parts of oyster extractives, 20 parts to 25 parts of pine bark extractives, 15 parts to 10 parts of kudzu vine root extractives and 10 parts to 15 parts of whinberry extractives. Compared with the prior art, the eye health care product capable of preventing and delaying senile macular degeneration has the advantages of effectively improving visual function, being accurate in effect and mechanism on health care function of visual function compared with other products sold in markets, and having excellent effects on preventing and curing other macular degeneration, diabetes mellitus complication fundus lesion and cataract.
Description
Technical field
The present invention relates to a kind of health product and preparation method thereof, especially relate to a kind of eye care article that prevent and delay the senile degeneration of macula function and preparation method thereof.
Background technology
Senile degeneration of macula was considered to a kind of unimportant global diseases causing blindness in the past, and was only relevant with a few peoples of developed country.Yet the Along with people's growth in the living standard, people's life expectancy has obtained prolongation, and especially in the Asia, this viewpoint has obtained challenge.According to the up-to-date blind person of World Health Organization (WHO) data estimation, three million peoples of surpassing are arranged because of the senile degeneration of macula blinding, account for 9% of blind person's sum, be only second to cataract and glaucoma.
Senile degeneration of macula (AMD) is the important oculopathy of blinding among the crowd more than 50 years old, one group of can not drive in the wrong direction visual deterioration or forfeiture being caused by retinal pigment epithelium and neural retina degeneration.Various countries, whole world epidemiological study mechanism is all paying close attention to the swift and violent increase of AMD sickness rate.In American-European countries, in the 52-64 stage in year, the AMD sickness rate is 2%; 75 years old and above stage, the AMD sickness rate reaches 28%, and to the year two thousand thirty, the sickness rate of AMD can increase by 50% again the America and Europe.In Japan, male AMD prevalence is 19.50% more than 50 years old, and the women is 14.90%.And in China, the sickness rate of different regions AMD is at 2.9%-12.9%; In Shanghai, city one hospital accomplishes one 100,000 people's special survey in the Bei Xinjing area, and the result shows; AMD has surpassed oculopathy such as glaucoma, detachment of retina, becomes the first cause of old blinding, in crowd more than 50 years old; The AMD sickness rate wherein has 5.1% blinding up to 15.5%.This shows the breaking with tremendous force of senile degeneration of macula.Again owing at present still do not have the efficacious therapy method, therefore to the prevention of AMD and delay its development and just had very large importance to AMD.
The epidemiological study data generally acknowledges that the main risk factor that senile degeneration of macula takes place comprises: diabetes medical history, age, dietary habit, solar radiation, video terminal radiation, smoking history etc. are relevant.Wherein the most key with dietary habit, solar radiation, smoking history especially.
The diabetes medical history: diabetics is owing to be in hyperglycemia state for a long time, and the high concentration existence of blood glucose causes the retinal microvascular pathological changes, thereby causes the macula retinae edema, and angiogenesis causes degeneration of macula.It has become one of severe complications in the diabetic complication, has a strong impact on diabetes patient's quality of life.
Dietary habit: have much relations similar with cardiovascular disease with dietary structure, the morbidity of dietary habit and senile degeneration of macula also has very big relation.Medical worker more than 70,000 is carried out the absorption of fat in the meals to Cho E and the relation between the AMD morbidity is discovered; A large amount of fat (as: linolenic acid) of taking in can make the danger that AMD takes place rise 49%; And take in unsaturated fatty acid (as: DHA), then make the incidence rate of AMD descend 30%.The absorption of ethanol is also influential to the sickness rate of AMD.Moss carries out finding in the BDES research, and the AMD sickness rate is 6.94 times of heavy drinker never in a large amount of drinks beer persons 10 years.The result of study of Cho E also shows, drinking amount is in the male more than 30g/ days, women, and the danger that AMD takes place is respectively 1.3 and 1.5 times of alcohol user not.And the research of Obisesan shows, drinks wine in right amount and can reduce the danger that AMD takes place.
Solar radiation: the investigation of BeaverDam ophthalmology seminar shows; There is positive correlation to get in touch between solar radiation and the AMD; After having mated age and sex factor; Be less than 2 hours physiognomy ratio with open-assembly time, every day have time more than 5 hours out of doors the person danger that retinal pigment increases with early stage AMD takes place increases.Tomany finds that AMD patient also is higher than matched group to sunlight sensitivity.
Smoking history: epidemiological study shows, smoking and AMD have a positive correlation.Kelly sp investigation shows that the chance that dryness and moist AMD take place the smoker is respectively 2.54 times and 4.55 times of the non-smoker, and the chance that once had the ES of smoking history to suffer from AMD is 1.36 times of smoker never.And smoking influence the mechanism of the incidence rate of AMD possibly comprise reduce the choroid blood flow, to reduce in the blood antioxidant level and RPE detoxification pathways unusual etc.
The pathogenesis of senile degeneration of macula is intricate, and unified understanding is not arranged so far as yet.But in recent years, along with the scientific research personnel shows through clinical and basic research, the senile degeneration of macula pathogenesis mainly contains following several approach.
The nonenzymatic glycosylation that hyperglycemia causes
Body in the environment of long-term hyperglycemia, the protein in glycosyl and the blood vessel wall, lipid generation glycosylation.This reaction will influence the characteristic of blood vessel, and the blood vessel wall permeability is changed, and interior environment and oxygen supply situation are organized in influence, thereby cause the generation of new vessels, concurrent AMD.
The retinal pigment epithelium apoptosis
Delpriore finds that along with the aging of human body, retinal pigment epithelium (RPE) apoptosis increases.Along with the RPE apoptosis increases, purple brown matter accumulation increases in the RPE.And purple brown matter can produce active oxygen, further destroys lysosome, makes further degeneration of RPE and apoptosis.Endochylema material in the RPE is drained into the Bruch film in a large number, causes the pathologic cell epimatrix to pile up, thereby forms the glass-film wart, and the morbidity of AMD is had great influence.Extracellular matrix is built up and is caused the Bruch film to thicken, and the supply of retina blood reduces, and causes the retinal ischemia anoxia, thereby stimulates choroid, near the angiogenesis of retina, thereby causes the generation of AMD.
The choroid supply of blood flow is not enough
Choroid supply of blood flow deficiency can cause the retinal pigment epithelium hypoxia, causes amphiblestroid anoxia, strengthens thereby induction of vascular generates factor active, produces CNV (CNV).And the formation of CNV can cause subretinal hemorrhage, is the main cause of AMD blinding.Therefore, improve choroid blood and supply that the prevention of AMD is had important meaning.
Oxidation reaction causes chain infringement
Purple brown matter in the RPE as photosensitizer, can produce active oxygen.Along with the increase and the body aging of active oxygen, the aggravation of visual cell oxidative damage, thus cause the photoreceptor apoptosis.Zarb research shows, organism aging process, infection, local anoxia, reperfusion injury, hematodinamics are undesired, radical damage all can produce active oxygen, thereby cause RPE and retina oxidative damage.Antioxidant system comprises sudismase, catalase, glutathion peroxidase, carotenoid, Vc, VE etc. in RPE and the retina.Yildirim measures and shows that AMD patient's catalase activity significantly is lower than healthy person, and the malonaldehyde level is higher than healthy person.Hahn finds that AMD eye macular area, RPE and Bruch film total iron content increase, and is prone to produce active hydroxy, causes degeneration of macula, thereby causes AMD.And in the carotenoid, phylloxanthin, cryptoxanthin can be protected the apoptosis of photoreceptor.Gale discovers that AMD ophthalmic retina phylloxanthin, cryptoxanthin obviously descend.
Because the AMD cause of disease is not clear and definite as yet, therefore many is main with exploratory therapy, comprising PDT, laser therapy, pupil heating therapy, radiotherapy, operative treatment etc.And drug treatment many be main to expand blood vessel class medicine, angiogenesis factor inhibitor, to suppress a platelet class cohesion type medicine.Chinese traditional treatment is main with QI invigorating silt class medicine then, and auxiliary treatment such as composite vitamin.In above therapeutic process, shortcoming such as exist that uncertain therapeutic efficacy is fixed, surgical risk, side effect are big, still pessimistic to the healing of AMD so far.Therefore, the prevention of AMD and the development that delays it are just become particularly important.
Along with the sickness rate of senile degeneration of macula increases year by year, and treatment means imperfection still.Various countries, whole world scientific research institution just progressively forwards attention the prevention of AMD to and delays and carried out the research of big input on the target of its development.
Experiment and EPDML investigation demonstration, high-caliber carotenoid in the blood plasma can reduce the sickness rate of AMD.Seddon jam research shows that the generation of the animal glass-film wart that carotenoid lacks can be accelerated.Brown NA research shows that retina receives the photic damage meeting to cause the decline of Vitamin C content in the retina, in feedstuff, adds vitamin C.Can strengthen the ability of retina photodamage resistant.
Calendar year 2001, the American National institute of ophthalmology carries out and has accomplished, and lasts the research of the AREDS by name that 10 years, 3640 people participates in.The double blinding clinical experiment has been adopted in research.Find that in result of study take zinc, vitamin C, vitamin E and carotenoid in the meals and make the sickness rate of AMD and dangerous development degree reduce by 25%, the risk factor of central vision reduces by 19%.AREDS is affirming that Combined application meals antioxidant for the effect while of preventing and delay AMD, also proposes, and the effect of using antioxidant separately is not as Combined application.Delcourt c finds that vitamin E has certain prevention to AMD and delays the effect of its development in the test of the POLA by name that 2584 people that France carries out participate in.
This shows the prevention of dietary supplement AMD and delay its development bigger meaning is arranged.
Summary of the invention
The object of the invention is exactly for the defective that overcomes above-mentioned prior art existence a kind of eye care article that prevent and delay the senile degeneration of macula function and preparation method thereof to be provided.
The object of the invention can be realized through following technical scheme:
A kind of eye care article that prevent and delay the senile degeneration of macula function is characterized in that, these health product comprise following component and weight portion content:
Chlorella extract 20-30;
Fructus actinidiae chinensis extract 10-25;
Concha Ostreae extract 15-20;
Cortex Pini Massonianae extract 20-25;
Radix Puerariae extract 5-10;
European Pericarpium Citri tangerinae extract 10-15.
Preferred following component of these health product and weight portion content: chlorella extract 25, Fructus actinidiae chinensis extract 20, Concha Ostreae extract 16, Cortex Pini Massonianae extract 23, Radix Puerariae extract 6, European Pericarpium Citri tangerinae extract 12.
Described chlorella extract adopts following method to obtain: with chlorella cell wall disruption, add the 50-60v/v% alcoholic solution, addition is 6-8 a times of chlorella volume, extracts twice under the 50-60 ℃ of temperature, obtains at 60 ℃ of following temperature concentrate dryings then.
Described Fructus actinidiae chinensis extract adopts following method to obtain: broken Fructus actinidiae chinensis, add the 50-60v/v% alcoholic solution, and addition is Fructus actinidiae chinensis 6-8 times, and soaking at room temperature is extracted and is spent the night, and 50 ℃ of following temperature concentrate dryings obtain.
Described Concha Ostreae extract adopts following method to obtain: broken Concha Ostreae, add Concha Ostreae volume 8-10 deionized water doubly, and extracted 2 hours under the 60-80 ℃ of temperature, extract twice, obtain at concentrate drying below 80 ℃ then.
Described Cortex Pini Massonianae extract adopts following method to obtain: pulverize Cortex Pini, add 8-10 times of deionized water of Cortex Pini volume, 60-80 ℃ of temperature extracted 2 hours; Extract twice; Extracting solution dams through 10K molecular weight film, gets the residue greater than 10K, and concentrate drying obtains below 80 ℃.
Described Radix Puerariae extract adopts following method to obtain: pulverize Radix Puerariae, add the 60-80v/v% alcoholic solution, addition is 6-8 a times of Radix Puerariae volume, and 60 ℃ are extracted twice, obtain at concentrate drying below 60 ℃ then.
Described European Pericarpium Citri tangerinae extract adopts following method to obtain: pulverize European Pericarpium Citri tangerinae, add the 95v/v% alcoholic solution, addition is European Pericarpium Citri tangerinae volume 6-8 times, and room temperature extracts twice, and extracting solution vacuum concentration postlyophilization below 50 ℃ obtains.
A kind of manufacture method of preventing and delaying the eye care article of senile degeneration of macula function may further comprise the steps:
(1) get the raw materials ready according to following component and weight portion content:
Chlorella extract 20-30,
Fructus actinidiae chinensis extract 10-25,
Concha Ostreae extract 15-20,
Cortex Pini Massonianae extract 20-25,
Radix Puerariae extract 5-10,
European Pericarpium Citri tangerinae extract 10-15;
(2) the said extracted thing is inserted in the mixer, stirred 15 minutes, cross 60 mesh sieves; Repeat above operation 3 times, mixture is added the 75v/v% alcoholic solution carry out wet granulation, wet granular is inserted 40-50 ℃ of drying in the baking box; Dried particles, dry grain crosses that filled capsules and tabletting get final product behind 40 mesh sieves.
Compared with prior art; The present invention can effectively improve visual function; Its health care to visual function is compared commercially available other products, and clear efficacy, mechanism are clear and definite more, and all have fabulous curative effect for the diabetes complicated retinopathy of other degeneration of macula, cataractous control.
The specific embodiment
Below in conjunction with specific embodiment the present invention is elaborated.
Embodiment 1
We are to 98 eyes of patient's 58 examples; Before and after examining treatment patient's vision, fundus photography, fundus fluorescein angiography, OCT check situation. 78 eyes treatments of result back vision has in various degree and improves, and the macular region hemorrhage absorption also stops repeatedly hemorrhagely, follows up a case by regular visits to 3 months～1 year; The state of an illness does not all have repeatedly; Vision 0.11～0.6,61 ocular choroid new vesselses dwindle, total effective rate 62.2%.Therefore, this product has certain prevention effect to degeneration of macula.
Embodiment 2
A kind of eye care article that prevent and delay the senile degeneration of macula function comprise following component and content:
Chlorella extract 20kg, Fructus actinidiae chinensis extract 10kg, Concha Ostreae extract 15kg, Cortex Pini Massonianae extract 20kg, Radix Puerariae extract 5kg, European Pericarpium Citri tangerinae extract 10kg.
Chlorella extract adopts following method to obtain: with chlorella cell wall disruption, add the 50v/v% alcoholic solution, addition is 6 times of chlorella volume, extracts twice under 50 ℃ of temperature, obtains at 60 ℃ of following temperature concentrate dryings then.
Fructus actinidiae chinensis extract adopts following method to obtain: broken Fructus actinidiae chinensis, add the 50v/v% alcoholic solution, and addition is 6 times of Fructus actinidiae chinensiss, and soaking at room temperature is extracted and is spent the night, and 50 ℃ of following temperature concentrate dryings obtain.
Concha Ostreae extract adopts following method to obtain: broken Concha Ostreae, the deionized water that adding Concha Ostreae volume is 8 times extracted 2 hours under 60 ℃ of temperature, extracted twice, obtained at concentrate drying below 80 ℃ then.
Cortex Pini Massonianae extract adopts following method to obtain: pulverize Cortex Pini, add 8 times of deionized waters of Cortex Pini volume, 60 ℃ of temperature were extracted 2 hours; Extract twice; Extracting solution dams through 10K molecular weight film, gets the residue greater than 10K, and concentrate drying obtains below 80 ℃.
Radix Puerariae extract adopts following method to obtain: pulverize Radix Puerariae, add the 60v/v% alcoholic solution, addition is 6 times of Radix Puerariae volume, and 60 ℃ are extracted twice, obtain at concentrate drying below 60 ℃ then.
The European Pericarpium Citri tangerinae extract adopts following method to obtain: pulverize European Pericarpium Citri tangerinae, add the 95v/v% alcoholic solution of 6 times of European Pericarpium Citri tangerinae volumes, room temperature extracts twice, and extracting solution vacuum concentration postlyophilization below 50 ℃ obtains.
The said extracted thing is inserted in the mixer, stirred 15 minutes, cross 60 mesh sieves; Repeat above operation 3 times, mixture is added the 75v/v% alcoholic solution carry out wet granulation, wet granular is inserted 40 ℃ of dryings in the baking box; Dried particles, dry grain crosses that filled capsules and tabletting get final product behind 40 mesh sieves.
Embodiment 3
A kind of eye care article that prevent and delay the senile degeneration of macula function comprise following component and content:
Chlorella extract 25kg, Fructus actinidiae chinensis extract 20kg, Concha Ostreae extract 16kg, Cortex Pini Massonianae extract 23kg, Radix Puerariae extract 6kg, European Pericarpium Citri tangerinae extract 12kg.
Chlorella extract adopts following method to obtain: with chlorella cell wall disruption, add the 55v/v% alcoholic solution, addition is 7 times of chlorella volume, extracts twice under 55 ℃ of temperature, obtains at 60 ℃ of following temperature concentrate dryings then.
Fructus actinidiae chinensis extract adopts following method to obtain: broken Fructus actinidiae chinensis, add the 55v/v% alcoholic solution, and addition is 7 times of Fructus actinidiae chinensiss, and soaking at room temperature is extracted and is spent the night, and 50 ℃ of following temperature concentrate dryings obtain.
Concha Ostreae extract adopts following method to obtain: broken Concha Ostreae, the deionized water that adding Concha Ostreae volume is 9 times extracted 2 hours under 70 ℃ of temperature, extracted twice, obtained at concentrate drying below 80 ℃ then.
Cortex Pini Massonianae extract adopts following method to obtain: pulverize Cortex Pini, add 9 times of deionized waters of Cortex Pini volume, 70 ℃ of temperature were extracted 2 hours; Extract twice; Extracting solution dams through 10K molecular weight film, gets the residue greater than 10K, and concentrate drying obtains below 80 ℃.
Radix Puerariae extract adopts following method to obtain: pulverize Radix Puerariae, add the 70v/v% alcoholic solution, addition is 7 times of Radix Puerariae volume, and 60 ℃ are extracted twice, obtain at concentrate drying below 60 ℃ then.
The European Pericarpium Citri tangerinae extract adopts following method to obtain: pulverize European Pericarpium Citri tangerinae, add the 95v/v% alcoholic solution, addition is 7 times of European Pericarpium Citri tangerinae volumes, and room temperature extracts twice, and extracting solution vacuum concentration postlyophilization below 50 ℃ obtains.
The said extracted thing is inserted in the mixer, stirred 15 minutes, cross 60 mesh sieves; Repeat above operation 3 times, mixture is added the 75v/v% alcoholic solution carry out wet granulation, wet granular is inserted 45 ℃ of dryings in the baking box; Dried particles, dry grain crosses that filled capsules and tabletting get final product behind 40 mesh sieves.
Embodiment 4
A kind of eye care article that prevent and delay the senile degeneration of macula function comprise following component and content:
Chlorella extract 30kg, Fructus actinidiae chinensis extract 25kg, Concha Ostreae extract 20kg, Cortex Pini Massonianae extract 25kg, Radix Puerariae extract 10kg, European Pericarpium Citri tangerinae extract 15kg.
Chlorella extract adopts following method to obtain: with chlorella cell wall disruption, add the 60v/v% alcoholic solution, addition is 8 times of chlorella volume, extracts twice under 60 ℃ of temperature, obtains at 60 ℃ of following temperature concentrate dryings then.
Fructus actinidiae chinensis extract adopts following method to obtain: broken Fructus actinidiae chinensis, add the 60v/v% alcoholic solution, and addition is 8 times of Fructus actinidiae chinensiss, and soaking at room temperature is extracted and is spent the night, and 50 ℃ of following temperature concentrate dryings obtain.
Concha Ostreae extract adopts following method to obtain: broken Concha Ostreae, the deionized water that adding Concha Ostreae volume is 10 times extracted 2 hours under 80 ℃ of temperature, extracted twice, obtained at concentrate drying below 80 ℃ then.
Cortex Pini Massonianae extract adopts following method to obtain: pulverize Cortex Pini, add 10 times of deionized waters of Cortex Pini volume, 80 ℃ of temperature were extracted 2 hours; Extract twice; Extracting solution dams through 10K molecular weight film, gets the residue greater than 10K, and concentrate drying obtains below 80 ℃.
Radix Puerariae extract adopts following method to obtain: pulverize Radix Puerariae, add the 80v/v% alcoholic solution, addition is 8 times of Radix Puerariae volume, and 60 ℃ are extracted twice, obtain at concentrate drying below 60 ℃ then.
The European Pericarpium Citri tangerinae extract adopts following method to obtain: pulverize European Pericarpium Citri tangerinae, add the 95v/v% alcoholic solution, addition is 8 times of European Pericarpium Citri tangerinae volumes, and room temperature extracts twice, and extracting solution vacuum concentration postlyophilization below 50 ℃ obtains.
The said extracted thing is inserted in the mixer, stirred 15 minutes, cross 60 mesh sieves; Repeat above operation 3 times, mixture is added the 75v/v% alcoholic solution carry out wet granulation, wet granular is inserted 50 ℃ of dryings in the baking box; Dried particles, dry grain crosses that filled capsules and tabletting get final product behind 40 mesh sieves.
Claims (9)
1. eye care article that prevent and delay the senile degeneration of macula function is characterized in that, these health product comprise following component and weight portion content:
Chlorella extract 20-30;
Fructus actinidiae chinensis extract 10-25;
Concha Ostreae extract 15-20;
Cortex Pini Massonianae extract 20-25;
Radix Puerariae extract 5-10;
European Pericarpium Citri tangerinae extract 10-15.
2. a kind of eye care article that prevent and delay the senile degeneration of macula function according to claim 1; It is characterized in that these health product comprise following component and weight portion content: chlorella extract 25, Fructus actinidiae chinensis extract 20, Concha Ostreae extract 16, Cortex Pini Massonianae extract 23, Radix Puerariae extract 6, European Pericarpium Citri tangerinae extract 12.
3. a kind of eye care article that prevent and delay the senile degeneration of macula function according to claim 1; It is characterized in that; Described chlorella extract adopts following method to obtain: with chlorella cell wall disruption, add the 50-60v/v% alcoholic solution, addition is 6-8 a times of chlorella volume; Extract twice under the 50-60 ℃ of temperature, obtain at 60 ℃ of following temperature concentrate dryings then.
4. a kind of eye care article that prevent and delay the senile degeneration of macula function according to claim 1; It is characterized in that; Described Fructus actinidiae chinensis extract adopts following method to obtain: broken Fructus actinidiae chinensis, add the 50-60v/v% alcoholic solution, and addition is Fructus actinidiae chinensis 6-8 times; Soaking at room temperature is extracted and is spent the night, and 50 ℃ of following temperature concentrate dryings obtain.
5. a kind of eye care article that prevent and delay the senile degeneration of macula function according to claim 1; It is characterized in that; Described Concha Ostreae extract adopts following method to obtain: broken Concha Ostreae, add Concha Ostreae volume 8-10 deionized water doubly, and extracted 2 hours under the 60-80 ℃ of temperature; Extract twice, obtain at concentrate drying below 80 ℃ then.
6. a kind of eye care article that prevent and delay the senile degeneration of macula function according to claim 1 is characterized in that, described Cortex Pini Massonianae extract adopts following method to obtain: pulverize Cortex Pini; Add 8-10 times of deionized water of Cortex Pini volume; 60-80 ℃ of temperature extracted 2 hours, extracted twice, and extracting solution dams through 10K molecular weight film; Get the residue greater than 10K, concentrate drying obtains below 80 ℃.
7. a kind of eye care article that prevent and delay the senile degeneration of macula function according to claim 1; It is characterized in that; Described Radix Puerariae extract adopts following method to obtain: pulverize Radix Puerariae, add the 60-80v/v% alcoholic solution, addition is 6-8 a times of Radix Puerariae volume; 60 ℃ are extracted twice, obtain at concentrate drying below 60 ℃ then.
8. a kind of eye care article that prevent and delay the senile degeneration of macula function according to claim 1; It is characterized in that; Described European Pericarpium Citri tangerinae extract adopts following method to obtain: pulverize European Pericarpium Citri tangerinae, add the 95v/v% alcoholic solution, addition is European Pericarpium Citri tangerinae volume 6-8 times; Room temperature extracts twice, and extracting solution vacuum concentration postlyophilization below 50 ℃ obtains.
9. a prevention as claimed in claim 1 and delay the manufacture method of the eye care article of senile degeneration of macula function is characterized in that this method may further comprise the steps:
(1) get the raw materials ready according to following component and weight portion content:
Chlorella extract 20-30,
Fructus actinidiae chinensis extract 10-25,
Concha Ostreae extract 15-20,
Cortex Pini Massonianae extract 20-25,
Radix Puerariae extract 5-10,
European Pericarpium Citri tangerinae extract 10-15;
(2) the said extracted thing is inserted in the mixer, stirred 15 minutes, cross 60 mesh sieves; Repeat above operation 3 times, mixture is added the 75v/v% alcoholic solution carry out wet granulation, wet granular is inserted 40-50 ℃ of drying in the baking box; Dried particles, dry grain crosses that filled capsules and tabletting get final product behind 40 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210027700.0A CN102526171B (en) | 2012-02-08 | 2012-02-08 | Eye health care product capable of preventing and delaying senile macular degeneration and manufacture method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210027700.0A CN102526171B (en) | 2012-02-08 | 2012-02-08 | Eye health care product capable of preventing and delaying senile macular degeneration and manufacture method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526171A true CN102526171A (en) | 2012-07-04 |
| CN102526171B CN102526171B (en) | 2014-02-19 |
Family
ID=46334992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210027700.0A Expired - Fee Related CN102526171B (en) | 2012-02-08 | 2012-02-08 | Eye health care product capable of preventing and delaying senile macular degeneration and manufacture method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526171B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104489553A (en) * | 2015-01-15 | 2015-04-08 | 四川省苍溪漓山粮油有限公司 | Kiwi fruit buccal tablet preparing method |
| CN106215168A (en) * | 2016-08-17 | 2016-12-14 | 吴冰滢 | Compositions of prevention Age related macular and preparation method thereof |
| CN110420173A (en) * | 2019-05-07 | 2019-11-08 | 南京医科大学眼科医院 | Application of the Puerarin gel eyedrop in preparation treatment macular degeneration disease drug |
| CN116211913A (en) * | 2017-10-04 | 2023-06-06 | 参天制药株式会社 | Composition for protecting retinal nerve cells comprising processed product of cowberry fruit and processed product of pine bark |
-
2012
- 2012-02-08 CN CN201210027700.0A patent/CN102526171B/en not_active Expired - Fee Related
Non-Patent Citations (10)
| Title |
|---|
| 晏兴云等: "原花青素在眼科的应用研究 ", 《国际眼科杂志》 * |
| 晏兴云等: "原花青素在眼科的应用研究", 《国际眼科杂志》, vol. 7, no. 04, 25 August 2007 (2007-08-25), pages 1095 - 1097 * |
| 胡济美等: "大兴安岭笃斯越橘花色苷成分鉴定研究 ", 《食品科学》 * |
| 胡济美等: "大兴安岭笃斯越橘花色苷成分鉴定研究", 《食品科学》, vol. 30, no. 10, 15 May 2009 (2009-05-15), pages 239 - 241 * |
| 谢晓燕: "年龄相关性黄斑变性的中医治疗概况 ", 《河南中医》 * |
| 谢晓燕: "年龄相关性黄斑变性的中医治疗概况", 《河南中医》, vol. 28, no. 04, 10 April 2008 (2008-04-10), pages 78 - 80 * |
| 邹文军等: "抗氧化营养素与老年性黄斑变性的防治 ", 《眼科学报》 * |
| 邹文军等: "抗氧化营养素与老年性黄斑变性的防治", 《眼科学报》, vol. 23, no. 04, 15 December 2007 (2007-12-15), pages 193 - 198 * |
| 郝宗娣等: "小球藻(Chlorella)活性成分的研究进展 ", 《食品工业科技》 * |
| 郝宗娣等: "小球藻(Chlorella)活性成分的研究进展", 《食品工业科技》, no. 12, 31 December 2010 (2010-12-31), pages 369 - 372 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104489553A (en) * | 2015-01-15 | 2015-04-08 | 四川省苍溪漓山粮油有限公司 | Kiwi fruit buccal tablet preparing method |
| CN104489553B (en) * | 2015-01-15 | 2017-06-09 | 四川省苍溪漓山粮油有限公司 | A kind of preparation method of Kiwi berry buccal tablet |
| CN106215168A (en) * | 2016-08-17 | 2016-12-14 | 吴冰滢 | Compositions of prevention Age related macular and preparation method thereof |
| CN116211913A (en) * | 2017-10-04 | 2023-06-06 | 参天制药株式会社 | Composition for protecting retinal nerve cells comprising processed product of cowberry fruit and processed product of pine bark |
| CN110420173A (en) * | 2019-05-07 | 2019-11-08 | 南京医科大学眼科医院 | Application of the Puerarin gel eyedrop in preparation treatment macular degeneration disease drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526171B (en) | 2014-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vats et al. | Anti-cataract activity of Pterocarpus marsupium bark and Trigonella foenum-graecum seeds extract in alloxan diabetic rats | |
| CN103566049B (en) | Regard the composition of macular degeneration disease in eyes regarding macular pigment optical density and prevention or treatment age related for improving | |
| CN104147081A (en) | Blueberry lutein soft capsule for improving eyesight and manufacturing method thereof | |
| CN103431390B (en) | Lycium ruthenicum eyesight improving preparation | |
| CN103977157A (en) | Lycium ruthenicum eyesight-improving eye-protecting tea | |
| CN103735733A (en) | Compound preparation containing lutein ester and preparation method thereof | |
| JP2008271878A (en) | Novel food and drink | |
| CN102526171B (en) | Eye health care product capable of preventing and delaying senile macular degeneration and manufacture method | |
| CN105362501A (en) | Radiation-preventing and eyesight-protecting beverage, and preparation method thereof | |
| CN105030877A (en) | Healthcare food for relieving asthenopia and preparation method thereof | |
| CN106539083A (en) | It is a kind of to be used to prevent and treat diabetic retinopathy, alleviate asthenopic compositionss | |
| CN104257727A (en) | Soft capsule for relieving visual fatigue and processing method | |
| CN101273994A (en) | Pharmaceutical composition for curing diabetic retina pathological changes and method of preparing the same | |
| CA2986975C (en) | Extract of cordyceps cicadae and its use for the manufacture of pharmaceutical composition for at least one of the prevention, delaying and treatment of cataracts | |
| CN105520137A (en) | Healthy food with functions of relieving asthenopia and protecting eyesight | |
| US20170136075A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases | |
| CN105106286A (en) | Health product with effects of protecting eyes and improving eyesight | |
| CN109731027A (en) | Facilitate the composition and preparation method thereof of alleviation visual fatigue and xerophthalmia series symptom | |
| CN104957618A (en) | Eye-protecting capsules with dendrobium officinale and fish oil | |
| CN105031248B (en) | It is a kind of containing selenium worm grass can auxiliary hyperglycemic health care product | |
| Mazzotta et al. | Riboflavin and the Cornea and Implications for Cataracts | |
| CN101390997B (en) | Jianmu capsule and preparation method thereof | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition | |
| CN105232640A (en) | Method of using cistanche tubulosa extract for preparing drugs or food to protect eye cells | |
| CN102940753A (en) | Pills for treating glaucoma and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140219 Termination date: 20160208 |